24/7 Market News Snapshot 13 February, 2025 – Pliant Therapeutics, Inc. Common Stock (NASDAQ:PLRX)

February 13, 2025

DENVER, Colo., 13 February, 2025 (247marketnews.com) – (NASDAQ:PLRX) are discussed in this article.
Pliant Therapeutics, Inc. (PLRX) is experiencing a notable bullish trend, with shares trading at $3.107 in the pre-market, reflecting a 14.23% increase over the last closing value of $2.720. This surge is accompanied by robust trading activity, with a volume of approximately 1.32 million shares exchanged, indicating heightened investor interest. Analysts suggest that if PLRX can sustain this upward movement and surpass crucial resistance levels, it may attract further buying interest, potentially leading to additional gains. Traders are advised to remain vigilant for any pullbacks at support levels to identify favorable buying opportunities. The technical indicators currently suggest a positive outlook for PLRX in the near term.

In tandem with its promising market performance, Pliant Therapeutics is advancing its clinical endeavors with the BEACON-IPF Phase 2b trial, which evaluates the investigational treatment bexotegrast for idiopathic pulmonary fibrosis (IPF). The company has established an expert panel at the recommendation of the independent Data Safety Monitoring Board (DSMB) to conduct an unblinded review of key trial data. This panel consists of distinguished specialists in pulmonary diseases and biostatistics who will assess the efficacy and safety data to guide potential enrollment resumption.

The panel’s assessment is anticipated to be completed within two to four weeks, following which their insights will be provided to the DSMB to determine the next steps for the trial. Prior to this development, Pliant had paused patient enrollment to perform a thorough analysis to maintain the study’s integrity. The ongoing efforts underline Pliant’s commitment to pioneering therapeutic advancements for fibrotic diseases, with bexotegrast positioned as a critical component of its portfolio, recently acknowledged for its potential by both the FDA and EMA.

Related news for (PLRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.